214 related articles for article (PubMed ID: 6187859)
1. Independent immunodominant and immunorecessive tumor-specific antigens on a malignant tumor: antigenic dissection with cytolytic T cell clones.
Wortzel RD; Urban JL; Philipps C; Fitch FW; Schreiber H
J Immunol; 1983 May; 130(5):2461-6. PubMed ID: 6187859
[TBL] [Abstract][Full Text] [Related]
2. Pecking order among tumor-specific antigens.
Urban JL; Van Waes C; Schreiber H
Eur J Immunol; 1984 Feb; 14(2):181-7. PubMed ID: 6230244
[TBL] [Abstract][Full Text] [Related]
3. Immune response to progressor variants derived from transfection of an ultraviolet radiation-induced C3H mouse regressor tumor cell line with activated Harvey-ras oncogene.
Kaba DS; Pierceall WE; Price JE; Ananthaswamy HN
Cancer Res; 1990 Jun; 50(11):3159-66. PubMed ID: 2185882
[TBL] [Abstract][Full Text] [Related]
4. Specificity of antigens on UV radiation-induced antigenic tumor cell variants measured in vitro and in vivo.
Hostetler LW; Romerdahl CA; Kripke ML
Cancer Res; 1989 Mar; 49(5):1207-13. PubMed ID: 2465081
[TBL] [Abstract][Full Text] [Related]
5. Immune response to somatic cell hybrids between ultraviolet radiation-induced regressor and spontaneous progressor C3H mouse tumor cells.
Chen PW; Kaba DS; Ananthaswamy HN
Cancer Res; 1990 Mar; 50(5):1544-9. PubMed ID: 2137370
[TBL] [Abstract][Full Text] [Related]
6. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones.
Maryanski JL; Boon T
Eur J Immunol; 1982 May; 12(5):406-12. PubMed ID: 6178608
[TBL] [Abstract][Full Text] [Related]
7. Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones.
Engers HD; Lahaye T; Sorenson GD; Glasebrook AL; Horvath C; Brunner KT
J Immunol; 1984 Sep; 133(3):1664-70. PubMed ID: 6205090
[TBL] [Abstract][Full Text] [Related]
8. Different phenotypic variants of the mouse B cell tumor A20/2J are selected by antigen- and mitogen-triggered cytotoxicity of L3T4-positive, I-A-restricted T cell clones.
Jones B; Tite JP; Janeway CA
J Immunol; 1986 Jan; 136(1):348-56. PubMed ID: 2415625
[TBL] [Abstract][Full Text] [Related]
9. Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance.
Ward PL; Koeppen HK; Hurteau T; Rowley DA; Schreiber H
Cancer Res; 1990 Jul; 50(13):3851-8. PubMed ID: 2112981
[TBL] [Abstract][Full Text] [Related]
10. Generation of antigenic variants from a nonantigenic murine tumor cell line by transfection with a gene encoding a novel tumor-specific transplantation antigen.
Kaba DS; McIntyre BW; Kripke ML; Goodenow RS; Schreiber H; Ananthaswamy HN
Cancer Res; 1989 Jan; 49(1):38-43. PubMed ID: 2783244
[TBL] [Abstract][Full Text] [Related]
11. In vitro selection of SV40 T antigen epitope loss variants by site-specific cytotoxic T lymphocyte clones.
Tanaka Y; Tevethia SS
J Immunol; 1988 Jun; 140(12):4348-54. PubMed ID: 2453578
[TBL] [Abstract][Full Text] [Related]
12. A rat anti-mouse T4 monoclonal antibody (H129.19) inhibits the proliferation of Ia-reactive T cell clones and delineates two phenotypically distinct (T4+, Lyt-2,3-, and T4-, Lyt-2,3+) subsets among anti-Ia cytolytic T cell clones.
Pierres A; Naquet P; Van Agthoven A; Bekkhoucha F; Denizot F; Mishal Z; Schmitt-Verhulst AM; Pierres M
J Immunol; 1984 Jun; 132(6):2775-82. PubMed ID: 6202760
[TBL] [Abstract][Full Text] [Related]
13. Expression of H-2 antigens and inducibility of antitumor immune responses in various tumor cell clones established from methylcholanthrene-induced fibrosarcomas.
Ogata M; Shimizu J; Kosaka H; Maekawa R; Shimizu K; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1986 Nov; 77(11):1134-41. PubMed ID: 3098723
[TBL] [Abstract][Full Text] [Related]
14. Induction of high-grade tumor-specific immunity in a host using a cytotoxic T-lymphocyte clone specific for a stable tumor antigen on murine leukemia L1210.
Rahman SM; Kawashima K; Nakashima I; Nagase F
Cancer Res; 1988 Nov; 48(22):6450-4. PubMed ID: 3263189
[TBL] [Abstract][Full Text] [Related]
15. Cloned cytolytic T cells can suppress primary cytotoxic responses directed against them.
Fink PJ; Rammensee HG; Bevan MJ
J Immunol; 1984 Oct; 133(4):1775-81. PubMed ID: 6332132
[TBL] [Abstract][Full Text] [Related]
16. Stepwise immunologic selection of antigenic variants during tumor growth.
Urban JL; Kripke ML; Schreiber H
J Immunol; 1986 Nov; 137(9):3036-41. PubMed ID: 3489784
[TBL] [Abstract][Full Text] [Related]
17. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
Sensi M; Orosz CG; Bach FH
J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
[TBL] [Abstract][Full Text] [Related]
18. T cell clones to two major T cell epitopes of myoglobin: effect of I-A/I-E restriction on epitope dominance.
Berkower I; Kawamura H; Matis LA; Berzofsky JA
J Immunol; 1985 Oct; 135(4):2628-34. PubMed ID: 2411806
[TBL] [Abstract][Full Text] [Related]
19. Comparison of tumor-associated transplantation antigens of sublines of methylcholanthrene-induced murine tumors passaged separately in vivo for over a decade.
Hines DL
Cancer Res; 1986 Oct; 46(10):4921-6. PubMed ID: 3489516
[TBL] [Abstract][Full Text] [Related]
20. Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro.
Van Waes C; Monach PA; Urban JL; Wortzel RD; Schreiber H
Tissue Antigens; 1996 May; 47(5):399-407. PubMed ID: 8795140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
